• KOL
    • Functional Dyspepsia
    • Nicholas Joseph Talley
    • Nicholas Joseph Talley: Influence Statistics

      Nicholas Joseph Talley

      Nicholas Joseph Talley

      Show email address

      School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; National Health and Medical Research Council Centre of Research Excellence on Digestive ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Nicholas Joseph Talley:Expert Impact

      Concepts for whichNicholas Joseph Talleyhas direct influence:Functional dyspepsia,Irritable bowel syndrome,Helicobacter pylori,Bowel syndrome,Irritable bowel,Gastrointestinal symptoms,Nonulcer dyspepsia,Celiac disease.

      Nicholas Joseph Talley:KOL impact

      Concepts related to the work of other authors for whichfor which Nicholas Joseph Talley has influence:Irritable bowel syndrome,Helicobacter pylori,Functional dyspepsia,Gastric cancer,Eosinophilic esophagitis,Gastroesophageal reflux disease,Abdominal pain.

      KOL Resume for Nicholas Joseph Talley

      Year
      2022

      School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; National Health and Medical Research Council Centre of Research Excellence on Digestive Health, Newcastle, Australia; Hunter Medical Research Institute, New Lambton Heights, Australia.

      College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia, Address: HMRI 349, HMRI Building, Callaghan, University Drive Callaghan, NSW 2308 Australia

      2021

      College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia

      Health Alliance on Climate Change, UK London, UK

      2020

      School of Medicine and Public Health, Faculty of Health & Medicine, University of Newcastle, Newcastle, NSW, Australia

      Faculty of Health and Medicine, University of Newcastle

      Translational Research in Gastrointestinal Diseases (TARGID), KU Leuven, Leuven, Belgium

      Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN

      Plant & Food Research, Research and Innovation Division, Hamilton, New Zealand

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Nicholas Joseph Talley is among the top experts in the world.
      Concept World rank
      diagnosis erosive gerd #1
      ileocolonic histopathological #1
      ssriinduced nausea #1
      alarm features ibs #1
      duodenal eosinophilia children #1
      non‐cardiac chest pain #1
      patients mm hg #1
      symptom relief subjects #1
      hpf ≥15 eos #1
      onset dyspepsia #1
      colorectal cancer crcancer #1
      ibs manning #1
      ifh pylori #1
      functional dyspepsia subjects #1
      sibo prevalence fd #1
      individual symptoms combinations #1
      data immunosuppressive therapy #1
      comorbid conditions fd #1
      new zealand summit #1
      diverticular disease ibd #1
      medical presentation constipation #1
      ibs rome criteria #1
      lottery ticket inducement #1
      qds placebo #1
      diagnosis esophageal eosinophilia #1
      dyspepsia female #1
      plasmacell dyscrasia #1
      imgej #1
      dyspepsia management guidelines #1
      rmiimq #1
      15 subjects placebo #1
      crc control population #1
      manning criteria subjects #1
      illness ibs #1
      asia–pacific consensus #1
      ibs dizygotic twins #1
      analgesics dyspepsia #1
      smd211 #1
      constipation gerd #1
      socially learned response #1
      dyspepsia definition #1
      chronic peptic ulceration #1
      scales nepean dyspepsia #1
      apoptosis gastric dysplasia #1
      prospective diary evaluation #1
      ndi functional dyspepsia #1
      babd standard biopsy #1
      antibiotic therapy ibd #1
      clinical isolates individuals #1
      placebo 6 bid #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Nicholas Joseph Talley

      KOL-Index: 20171

      OBJECTIVES: Helicobacter pylori is a carcinogen; gastric carcinoma involves a multistep process from chronic gastritis to atrophy, intestinal metaplasia, and dysplasia. The aims of this study were to determine the types of mucosa at different gastric sites in H. pylori-infected and uninfected patients, and whether the presence of antral-type mucosa in the incisura, body, and fundus is associated with gastric atrophy and intestinal metaplasia.

      METHODS: Two hundred and sixty-eight patients ...

      Known for Intestinal Metaplasia | Gastric Incisura | Helicobacter Pylori | Atrophic Gastritis | Type Mucosa
      KOL-Index: 16390

      OBJECTIVES: Helicobacter pylori is an identified carcinogen for gastric cancer, however, the underlying mechanisms remain to be defined. In this review, we sought to elucidate the role of apoptosis in gastric carcinogenesis, to determine the influence of H. pylori infection on apoptosis, and finally to provide insights into the mechanisms by which H. pylori may lead to gastric carcinogenesis.

      METHODS: A broad-based MEDLINE and Current Contents literature search was performed to identify ...

      Known for Gastric Carcinogenesis | Pylori Infection | Cell Proliferation | Intestinal Metaplasia | Underlying Mechanisms
      KOL-Index: 16214

      Background: Patient-rated symptom assessments are needed for evaluating the effectiveness of medical treatments and for monitoring outcomes in gastroparesis. Objective: This paper summarizes the development and psychometric evaluation of a new instrument, the Gastroparesis Cardinal Symptom Index (GCSI), for assessing severity of symptoms associated with gastroparesis. Methods: The GCSI was based on reviews of the medical literature, patient focus groups, and interviews with clinicians. A ...

      Known for Gastroparesis Symptoms | Patients Gcsi | Symptom Severity | United States | Total Score
      KOL-Index: 15761

      OBJECTIVES: Helicobacter pylori (H. pylon) infection seems to induce antralization (ie., gastric mucosal transformation from transitional or body type to antral type), which is strongly associated with gastric atrophy and intestinal metaplasia. The aim of this study was to determine the topographic associations of Ki-67 (a protein expressed in proliferative cells), Bax (a pro-apoptotic protein), and Bcl-2 (an antiapoptotic protein) expression with antralization.

      METHODS: In each of 104 ...

      Known for Gastric Incisura | Pylori Infection | Bax Bcl2 | Epithelial Expression | Intestinal Metaplasia
      KOL-Index: 15453

      OBJECTIVE: To assess the prevalence of combined fecal and urinary incontinence.

      DESIGN: A cross-sectional, community-based study.

      SETTING: Olmsted County, Minnesota.

      PARTICIPANTS: Men (n = 778) and women (n = 762), aged 50 years or older, selected randomly from the population.

      MEASUREMENTS: Participants completed a previously validated self-administered questionnaire that assessed the occurrence of fecal and urinary incontinence in the previous year.

      RESULTS: The age-adjusted prevalence ...

      Known for Urinary Incontinence | Women Prevalence | Combined Fecal | Crosssectional Studies | Previous Year
      KOL-Index: 15221

      INTRODUCTION: We conducted a systematic review and meta-analysis to compare the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS) and controls.

      METHODS: Electronic databases were searched up to December 2018 for studies reporting SIBO prevalence in patients with IBS. Prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) of SIBO in patients with IBS and controls were calculated.

      RESULTS: We included 25 studies with ...

      Known for Patients Ibs | Irritable Bowel Syndrome | Sibo Prevalence | Controls 95 | Bacterial Overgrowth
      KOL-Index: 15214

      BACKGROUND: On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.

      AIM: To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.

      PATIENTS AND METHODS: Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = ...

      Known for 6 Months | Esomeprazole 40 | Demand Therapy | Oesophageal Reflux Disease | Term Management
      KOL-Index: 14942

      BACKGROUND: Disturbed bowel habit, diarrhoea or constipation is a key manifestation of irritable bowel syndrome (IBS). In some patients, diarrhoea and constipation alternate, giving rise to the so-called alternating subtype.

      AIMS: To assess IBS subtype breakdown (constipation (C-IBS), diarrhoea (D-IBS) or alternating (A-IBS)) according to the Rome II criteria and patients' self-assessment, the predominance in the alternating subtype (i.e. constipation, diarrhoea or neither), and the ...

      Known for Rome Criteria | Ibs Subtypes | Bowel Habit | Constipation Diarrhoea | Health Quality Life
      KOL-Index: 14898

      OBJECTIVES: Proton pump inhibitors reduce ulcer recurrence in non-steroidal anti-inflammatory drug (NSAID) users, but their impact in at-risk ulcer-free patients using the current spectrum of prescribed agents has not been clearly defined. We assessed esomeprazole for ulcer prevention in at-risk patients (> or = 60 yr and/or ulcer history) taking NSAIDs, including COX-2 inhibitors. Such studies are particularly relevant, given that concerns regarding adverse cardiovascular outcomes among ...

      Known for 2 Inhibitors | Placebo Esomeprazole | 6 Months | Nonselective Nsaids | Risk Ulcer
      KOL-Index: 14484

      OBJECTIVE: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder. Evidence for treatment of the condition with antidepressants and psychological therapies is conflicting.

      DESIGN: Systematic review and meta-analysis of randomised controlled trials (RCTs). MEDLINE, EMBASE and the Cochrane Controlled Trials Register were searched (up to May 2008).

      SETTING: RCTs based in primary, secondary and tertiary care.

      PATIENTS: Adults with IBS.

      INTERVENTIONS: Antidepressants ...

      Known for Psychological Therapies | Antidepressants Placebo | Treatment Ibs | Irritable Bowel | Control Therapy
      KOL-Index: 14385

      INTRODUCTION: Motilin-receptor agonists are prokinetics; whether they relieve the symptoms of functional dyspepsia is unknown. We aimed to test the efficacy of the motilin agonist ABT-229 in functional dyspepsia patients with and without delayed gastric emptying.

      METHODS: Patients were randomized with postprandial symptoms and documented functional dyspepsia by endoscopy (n=589 in intention-to-treat analysis). Patients were assigned to either the delayed or normal gastric emptying ...

      Known for Delayed Gastric | Functional Dyspepsia | Patients Placebo | Motilin Receptor Agonist | 4 Weeks
      KOL-Index: 14289

      OBJECTIVE: The diagnostic value of the addition of alarm symptoms in distinguishing functional from organic gastrointestinal disease remains uncertain. We aimed to establish the value of alarm features in differentiating between organic disease and irritable bowel syndrome (IBS) and functional dyspepsia (FD).

      METHODS: A total of 568 consecutive patients (63% female; mean age 44.7 years) completed a detailed symptom questionnaire and then received a complete diagnostic workup, as ...

      Known for Alarm Features | Diagnostic Yield | Bowel Syndrome | Diagnosis Ibs | Organic Disease
      KOL-Index: 14254

      OBJECTIVE: To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.

      DESIGN: Systematic review and meta-analysis of randomised controlled trials.

      DATA SOURCES: Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. ...

      Known for Peppermint Oil | Irritable Bowel Syndrome | Antispasmodics Placebo | Persistent Symptoms | Randomized Controlled Trials
      KOL-Index: 13969

      BACKGROUND: Irritable bowel syndrome (IBS) prevalence estimates are essential for measuring the importance of the problem and the burden of the illness. However, IBS diagnosis is based on clinical criteria which have changed over time. The aim of this study was to assess how the use of different diagnostic criteria influences estimated IBS prevalence and, in particular, to compare how this prevalence varies using the new Rome II criteria and previous diagnostic criteria.

      METHODS: An ...

      Known for Ibs Rome | Manning Criteria | Irritable Bowel | Epidemiological Survey | Prevalence Varies
      KOL-Index: 13938

      BACKGROUND & AIMS: Empirical therapy has been proposed for initial management of dyspepsia. The aim of this study was to evaluate initial endoscopy, empirical therapy, and testing for Helicobacter pylori in the management of patients with a new onset of dyspepsia.

      METHODS: Decision analysis was used to compare the direct medical charges in the first year after the onset of dyspepsia for patients managed by initial endoscopy or empirical therapy, with or without initial testing for H. ...

      Known for Initial Endoscopy | Empirical Therapy | Helicobacter Pylori | Patients Dyspepsia | Decision Analysis

      Key People For Functional Dyspepsia

      Top KOLs in the world
      #1
      Nicholas Joseph Talley
      functional dyspepsia irritable bowel syndrome emergency action
      #2
      Vincenzo Stanghellini
      irritable bowel syndrome functional dyspepsia gastric emptying
      #3
      Jan F Tack
      functional dyspepsia irritable bowel syndrome chronic constipation
      #4
      Camilleri Camilleri
      irritable bowel syndrome colonic transit gastric emptying
      #5
      Gerald J Holtmann
      functional dyspepsia irritable bowel syndrome inflammatory bowel disease
      #6
      Juan‐R Malagelada
      functional dyspepsia abdominal bloating intestinal gas

      School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; National Health and Medical Research Council Centre of Research Excellence on Digestive Health, Newcastle, Australia; Hunter Medical Research Institute, New Lambton

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.